Log In
BCIQ
Print this Print this
 

Jardiance, empagliflozin (BI-10773)

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsPrevent cardiovascular death in adults with Type II diabetes and cardiovascular disease; Treat Type II diabetes
Regulatory Designation U.S. - Undisclosed Review (Treat Type II diabetes);
EU - Standard Review (Treat Type II diabetes);
Japan - Standard Review (Treat Type II diabetes)
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$2,367.9M

$386.0M

$1,456.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/17/2011

$2,367.9M

$386.0M

$1,456.0M

Get a free BioCentury trial today